Class 564/180 - Polycyclo ring system in substituent Q

Subclass of Class 564 - Organic compounds -- part of the class 532-570 series
Definition: Compounds wherein the carboxylic acid residue contains a
No. of applications: 29
Last issue date: 12/15/2011

Application No.	Application Title	Issue Date
20110306621	ACYLGUANIDINE DERIVATIVES An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT_5Areceptor modulating action. It was confirmed that acylguanidine derivatives, which...	12/15/2011
20110269834	COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS)....	11/03/2011
20110256549	Novel reagents for directed biomarker signal amplification Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. ...	10/20/2011
20110237798	DIRECT CONVERSION OF PHENOLS INTO AMIDES AND ESTERS OF BENZOIC ACID A method is provided for the preparation of an aromatic carboxylic acid aryl ester or an N-aryl aromatic carboxamide. The method comprises contacting an O,O-diaryl thiocarbonate or an O-aryl-N-aryl thiocarbamate with a reactant that regioselectively reacts with sulfur, ...	09/29/2011
20110196147	INHIBITORS OF HISTONE DEACETYLASE This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein	08/11/2011
20110172185	THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a...	07/14/2011
20100286445	METHOD OF FINISHING ORGANIC PIGMENTS A method of finishing an organic pigment that involves dissolving or dispersing the pigment in a mineral acid and crystallizing the pigment from the solution or dispersion by mixing with an aqueous diluent in the absence of a sulfonato-functional condensation product of...	11/11/2010
20100279001	CARBON NANO-TUBE (CNT) THIN FILM TREATED WITH CHEMICAL HAVING ELECTRON WITHDRAWING FUNCTIONAL GROUP AND MANUFACTURING METHOD THEREOF Disclosed are a carbon nano-tube (CNT) thin film treated with chemical having an electron withdrawing functional group and a manufacturing method thereof. Specifically, the CNT thin film comprises a CNT composition to be applied on a plastic substrate. The CNT compositi...	11/04/2010
20100144778	Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included. ...	06/10/2010
20100087480	SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprisi...	04/08/2010
20100087496	NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS This invention relates to novel cinnamic amide derivatives that are found to be potent modulators of ion channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of ion channels...	04/08/2010
20100061928	LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS The present invention relates to the use of a compound of formula (I): in which ...	03/11/2010
20100022547	Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectiv...	01/28/2010
20090176993	Calcium receptor active compounds A novel calcium receptor active compound having the formula is provided: Ar₁—[CR¹R²]_p—X—[CR³R⁴]_q—[CR⁵R⁶	07/09/2009
20090137420	METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of-function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene ...	05/28/2009
20080319082	Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives Biphenyl and phenyl-naphthyl compounds bearing a hydroxamic group, which are endowed with antitumour, and anti-angiogenic activity These compounds are therefore particularly useful for the treatment of drug-resistant tumours....	12/25/2008
20080318779	Fungicidal Composition Containing Acid Amide Derivative Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases tends to be inadequate depending upo...	12/25/2008
20080269282	Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its asso...	10/30/2008
20080249130	Gut microsomal triglyceride transport protein inhibitors Compounds represented by formula (I): are inhibitors of gut microsomal triglyceride transfer protein. Such compounds are useful in treating diseases or conditions such as diabetes and obesity, along with pati...	10/09/2008
20080242877	Intermediates and processes for the synthesis of Ramelteon Provided are intermediates and processes for preparation of Ramelteon....	10/02/2008
20080234334	1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS This invention is directed to compounds of formula I, where G is —O—, —S—, —C(g₁)(g₂)-, or —NH—, and n=1, 2, or 3. Such compounds modulate potassium channels. The compounds...	09/25/2008
20080171788	Medicament For Irritable Bowel Syndrome The invention relates to a medicament for IBS, which comprises a dual antagonist for 5-HT_2Band 5-HT₇receptors having selective binding affinities for 5-HT_2Band 5-HT₇receptors. The pharmaceutic...	07/17/2008
20080125491	Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Cell Death-Related Disorders The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle ...	05/29/2008
20080070918	Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q₁, Q₂, Q₃, R₃, and R₄are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or con...	03/20/2008
20080064693	N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR⁶, SO or SO₂; R¹represent hydrogen, cyano, hydroxy, or C_1-4al...	03/13/2008
20070299101	Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL lev...	12/27/2007
20070298123	ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for e...	12/27/2007
20070082957	Adamantane derivatives The invention provides adamantane derivatives of formula (I), a process for the their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH₂...	04/12/2007
20060258748	Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders This invention relates to diamondoid derivatives which exhibit therapeutic activity. Specifically, the diamondoid derivatives herein exhibit therapeutic effects in the treatment of neurologic disorders. Also provided are methods of treatment, prevention and inhibition o...	11/16/2006

PatentStorm

Quotables

PatentStorm News

Class 564/180 - Polycyclo ring system in substituent Q